{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:27:10Z","timestamp":1778696830683,"version":"3.51.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Lupus is a diverse autoimmune disease with autoantibody formation. Lupus nephritis carries a grave prognosis. Complement involvement, namely, C1q deficiency, is linked to activity and renal involvement and could help in their assessment. LN therapies include plasma exchange, immune adsorption, and probably hemodiafiltration with online endogenous reinfusion (HFR), together with traditional immunosuppressive therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of this study was to evaluate the role of HFR in improving signs and symptoms of systemic lupus erythematosus (SLE) activity and laboratory parameters in cases not responding to traditional immunosuppressive therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Settings and design<\/jats:title><jats:p>A controlled clinical study was conducted on 60 patients with lupus from Group A that was subdivided into two groups: cases 1 (47 patients), those who received traditional medical treatment, and cases 2 (13 patients), those who underwent HFR in addition to medical treatment. Group B consisted of two subgroups: control 1, composed of 20 healthy age- and sex-matched volunteers, and control 2, consisting of 10 cases with different glomerular diseases other than lupus.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and materials<\/jats:title><jats:p>Serum C1q was determined before and after the HFR as well as induction by medical treatment. Disease activity was assessed using SLEDAI-2K with a responder index of 50; quality of life was assessed using SLEQOL v2, and HFR was performed for the non-responder group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>C1q was lower in cases. It can efficiently differentiate between SLE patients and healthy controls with a sensitivity of 81.67% and a specificity of 90%. It can also efficiently differentiate between SLE patients and the control 2 group (non-lupus patients with renal glomerular disease) with a sensitivity of 83.33% and a specificity of 100%. C1q was more consumed in proliferative lupus, and correlated with anti-ds DNA, C3, and C4.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>C1q efficiently discriminates lupus patients and correlates with proliferative forms. HFR might ameliorate lupus activity and restore C1q.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneph.2024.1269852","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T07:00:26Z","timestamp":1711090826000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of online hemodiafiltration with endogenous reinfusion in the treatment of systemic lupus erythematosus activity resistant to conventional therapy"],"prefix":"10.3389","volume":"4","author":[{"given":"Mohammed A.","family":"Elghiriani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salah S.","family":"Naga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibtessam A.","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman E.","family":"Elgohary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal R.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22502","article-title":"Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States","volume":"67","author":"Jarukitsopa","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/art.22641","article-title":"Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data","volume":"56","author":"Chakravarty","year":"2007","journal-title":"Arthritis Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2004.04.002","article-title":"Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus","volume":"3","author":"Borchers","year":"2004","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1053\/berh.2001.0228","article-title":"Can morbidity and mortality of SLE be improved","volume":"16","author":"Bongu","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus","volume":"41","author":"Cooper","year":"1998","journal-title":"Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra071297","article-title":"Systemic lupus erythematosus","volume":"358","author":"Rahman","year":"2008","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus","volume":"369","author":"D'Cruz","year":"2007","journal-title":"Lancet"},{"key":"B10","unstructured":"What are the risk factors for developing lupus"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"B12","first-page":"133","article-title":"Complement and complement fixation","volume-title":"Experimental immunochemestriy","author":"Mayer","year":"1961"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)80301-X","article-title":"C1q: structure, function, and receptors","volume":"49","author":"Kishore","year":"2000","journal-title":"Immunopharmacology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M307764200","article-title":"The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties","volume":"278","author":"Gaboriaud","year":"2003","journal-title":"J Biol Chem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1212753109","article-title":"C1q limits dendritic cell differentiation and activation by engaging LAIR-1","volume":"109","author":"Son","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.400168","article-title":"C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-beta neurotoxicity","volume":"288","author":"Benoit","year":"2013","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2011.10.008","article-title":"Human complement Factor H modulates C1q-mediated phagocytosis of apoptotic cells","volume":"217","author":"Kang","year":"2012","journal-title":"Immunobiology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100724","article-title":"Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50","volume":"38","author":"Touma","year":"2011","journal-title":"J Rheumatol"},{"key":"B19","article-title":"Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains","volume":"26","author":"Smolen","year":"1999","journal-title":"J Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2009.39","article-title":"Recent insights into the genetic basis of systemic lupus erythematosus","volume":"10","author":"Moser","year":"2009","journal-title":"Genes Immun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-4310(00)01798-6","article-title":"Molecular aberrations in human systemic lupus erythematosus","volume":"6","author":"Tsokos","year":"2000","journal-title":"Mol Med Today"},{"key":"B22","article-title":"Biostatistics","volume-title":"A foundation for analysis in the health science","author":"Daniel","year":"1995"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000381395","article-title":"Radical improvement of signs and symptoms in systemic lupus erythematosus when treated with hemodiafiltration with endogenous reinfusion dialysis","volume":"5","author":"Solano","year":"2015","journal-title":"Case Rep Nephrol Dial"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024943","article-title":"Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus","volume":"64","author":"Marto","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1749-6632.2009.04746.x","article-title":"Anti-C1q autoantibodies in lupus nephritis","volume":"1173","author":"Sinico","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2010.07.009","article-title":"Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus","volume":"156","author":"Mok","year":"2010","journal-title":"Transl Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.08.010","article-title":"Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis","volume":"90","author":"Pang","year":"2016","journal-title":"Kidney Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12178","article-title":"Effect of hemodiafiltration with endogenous reinfusion on overt idiopathic chronic inflammation in maintenance hemodialysis patients: a multicenter longitudinal study","volume":"18","author":"Borrelli","year":"2014","journal-title":"Hemodial Int"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006070767","article-title":"Urine biomarkers predict the cause of glomerular disease","volume":"18","author":"Varghese","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-014-0130-8","article-title":"A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR)","volume":"28","author":"Pasquali","year":"2015","journal-title":"J Nephrol"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2024.1269852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T07:00:31Z","timestamp":1711090831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2024.1269852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,22]]},"references-count":30,"alternative-id":["10.3389\/fneph.2024.1269852"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2024.1269852","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,22]]},"article-number":"1269852"}}